LDHB and leukemia: This mechanism highlights circTET2 as a novel therapeutic target for managing the disease (110).Furthermore, R-2-hydroxyglutarate dampens aerobic glycolysis in leukemia through the FTO/m6A/PFKP/LDHB signaling axis, offering a potential therapeutic approach for modulating leukemia metabolism (111).